With respect to previous findings in other tumors and based on the results of this study, high STING expression in laryngeal cancer is a favorable biomarker candidate for potential therapeutic approaches employing STING agonists and ICIs in combination with DNA-damaging therapies (radiotherapy, cisplatin, and PARP inhibitors). The gene discussed is STING1; the disease is laryngeal carcinoma.